Vertex Pharmaceuticals Inc (NASDAQ:VRTX) — Market Cap & Net Worth
Market Cap & Net Worth: Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a market capitalization of $107.56 Billion ($107.56 Billion) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #223 globally and #118 in its home market, demonstrating a -2.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vertex Pharmaceuticals Inc's stock price $423.92 by its total outstanding shares 253718831 (253.72 Million). Analyse how efficiently does Vertex Pharmaceuticals Inc generate cash to see how efficiently the company converts income to cash.
Vertex Pharmaceuticals Inc Market Cap History: 2015 to 2026
Vertex Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $31.93 Billion to $107.56 Billion (13.09% CAGR).
Index Memberships
Vertex Pharmaceuticals Inc is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$910.33 Billion | 11.82% | #3 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.09 Trillion | 9.88% | #4 of 39 |
|
S&P 500 Index
GSPC
|
$59.46 Trillion | 0.27% | #98 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 4.46% | #5 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.28% | #41 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 6.45% | #4 of 263 |
|
Nasdaq 100
NDX
|
$32.64 Trillion | 0.33% | #40 of 101 |
Weight: Vertex Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vertex Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vertex Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.58x
Vertex Pharmaceuticals Inc's market cap is 9.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.10x
Vertex Pharmaceuticals Inc's market cap is 29.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $18.69 Billion | $1.70 Billion | -$112.05 Million | 10.98x | N/A |
| 2017 | $38.02 Billion | $2.49 Billion | $263.48 Million | 15.28x | 144.31x |
| 2018 | $42.04 Billion | $3.05 Billion | $2.10 Billion | 13.80x | 20.05x |
| 2019 | $55.55 Billion | $4.16 Billion | $1.18 Billion | 13.34x | 47.21x |
| 2020 | $59.96 Billion | $6.21 Billion | $2.71 Billion | 9.66x | 22.11x |
| 2021 | $55.72 Billion | $7.57 Billion | $2.34 Billion | 7.36x | 23.79x |
| 2022 | $73.27 Billion | $8.93 Billion | $3.32 Billion | 8.20x | 22.06x |
| 2023 | $103.24 Billion | $9.87 Billion | $3.62 Billion | 10.46x | 28.52x |
| 2024 | $102.17 Billion | $11.02 Billion | -$535.60 Million | 9.27x | N/A |
| 2025 | $115.03 Billion | $12.00 Billion | $3.95 Billion | 9.58x | 29.10x |
Competitor Companies of VRTX by Market Capitalization
Companies near Vertex Pharmaceuticals Inc in the global market cap rankings as of May 3, 2026.
Key companies related to Vertex Pharmaceuticals Inc by market ranking:
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #585 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #585 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Vertex Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Vertex Pharmaceuticals Inc's market cap moved from $31.93 Billion to $ 107.56 Billion, with a yearly change of 13.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $107.56 Billion | -6.49% |
| 2025 | $115.03 Billion | +12.58% |
| 2024 | $102.17 Billion | -1.03% |
| 2023 | $103.24 Billion | +40.90% |
| 2022 | $73.27 Billion | +31.50% |
| 2021 | $55.72 Billion | -7.08% |
| 2020 | $59.96 Billion | +7.94% |
| 2019 | $55.55 Billion | +32.13% |
| 2018 | $42.04 Billion | +10.58% |
| 2017 | $38.02 Billion | +103.42% |
| 2016 | $18.69 Billion | -41.45% |
| 2015 | $31.93 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Vertex Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $107.56 Billion USD |
| MoneyControl | $107.56 Billion USD |
| MarketWatch | $107.56 Billion USD |
| marketcap.company | $107.56 Billion USD |
| Reuters | $107.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more